Journal of Evolving Stem Cell Research
ISSN: 2574-4372
Current Issue
Volume No: 1 Issue No: 2
share this page

Research Article | Open Access
  • Available online freely | Peer Reviewed
  • | Provisional

    A Role for in Vitro Disease Models in the Landscape of Preclinical Cardiotoxicity and Safety Testing

    Vijayalakshmi Varma 1      

    1Biomarkers and Alternative Models Branch, Division of Systems Biology, National Center for Toxicological Studies, Jefferson, AR

    Abstract

    Drug-induced cardiotoxicity is one of the predominant reasons for drug attrition and withdrawals. This is of critical concern when potentially cardiotoxic drugs are administered to individuals with inherited arrhythmogenic cardiac diseases or with metabolic diseases such as obesity and diabetes, which are key risk factors for cardiovascular diseases. Pathophysiological alteration prevalent under such conditions can alter or exacerbate cardiotoxic responses. The growing incidence of obesity, diabetes and metabolic syndrome subject a significant percentage of the population to drug treatments, thereby augmenting their risk for drug-induced cardiovascular toxicity. Hence, screening for drug-induced cardiotoxicity early in the preclinical stages of drug development, by using appropriate human disease models, can be effective in ensuring safety in clinical trials and preventing late stage and post-marketing drug withdrawals owing to cardiotoxicity. The advent of human pluripotent stem cells (hPSC) and induced pluripotent stem cell (iPSC)-derived cardiomyocytes are revolutionizing safety/toxicity screening in human cells by providing relevant human-specific, renewable model systems to explore human drug toxicity. The ability to generate patient-specific iPSCs that can model cardiac diseases, now offers a valuable option that can further improve drug safety assessments and enable a more accurate prediction of toxicity that occurs in the representative population that are prescribed the drugs. Use of appropriate disease models will not only provide cost savings by decreasing potential drug attrition and withdrawals, seen with many drugs, but will also be a promising option to advance precision medicine

    Received 13 Jul 2017; Accepted 21 Jul 2017; Published 29 Jul 2017;

    Academic Editor:Fernando Luiz Affonso Fonseca, Head of Laboratório de Análises Clínicas da Faculdade de Medicina do ABC, Santo André, SP, Brazil.

    Checked for plagiarism: Yes

    Review by: Single-blind

    Copyright©  2017 Vijayalakshmi Varma, et al.

    License
    Creative Commons License    This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    Competing interests

    The authors have declared that no competing interests exist.

    Citation:

    Vijayalakshmi Varma (2017) A Role for in Vitro Disease Models in the Landscape of Preclinical Cardiotoxicity and Safety Testing. Journal of Evolving Stem Cell Research - 1(2):27-34.
    Download as RIS, BibTeX, Text (Include abstract )
    DOI10.14302/issn.2574-4372.jesr-17-1705

    Introduction

    The drug development pipeline is an arduous, labor-intensive and expensive process that entails stringent regulations by the FDA, in order to ensure the final marketed drug will be safe and efficacious for use in all patients that are prescribed the drugs 1, 2, 3. Although rigorous screening and testing of drugs occur as part of preclinical studies and clinical trials, safety and toxicity continue to be leading causes for the withdrawal of drugs from the markets 1, 4, 5. Amongst specific organ toxicities, cardiac toxicity is one of the predominant reasons for late-stage attrition of drugs 6, 7, 8. A potential reason for late-stage drug attrition and post-marketing withdrawals may be attributed to drug-induce cardiotoxicity augmented by cardiovascular risk factors that are prevalent in many patients with metabolic disorders such as obesity (36% of the population 9 type II diabetes (9.3% of the population 10, and metabolic syndrome (~35% of the population) 11. Such patients are usually not part of clinical trials, unless the clinical trial is specifically for anti-diabetic or anti-obesity drugs. Thus, drugs prescribed to a significant percentage of the population displaying cardiovascular risk factors put them at a higher risk for drug-induced cardiovascular toxicity.

    Cardiovascular adverse events can result when drugs impact either the structural and functional aspects of the different components of the cardiovascular system including cardiac myocytes, fibroblasts, vascular smooth muscle cells and endothelial cells lining the vasculature, or affect the electrical conductivity of the heart or a combination of both, resulting in cardiac dysfunction 12. Conditions that mediate drug-induced cardiotoxicity include 1) Cardiac arrhythmias; which results from the altered electrical conductivity of the heart causing tachycardia, brachycardia, ventricular fibrillation or asystole. 13 Torsade de pointes, is a dangerous form of ventricular arrhythmia, that is commonly triggered by cardiotoxic drugs 14. It is characterized by tachycardia and associated with a prolonged QT interval in an electrocardiogram 12. 2) Cardiac hypertrophy: This results from the increased size of the cardiomyocytes consequent to decreased or compromised cardiac function 15. 3) Cardiomyopathy: This is a condition that manifests due to structural and functional alterations in the heart resulting in decreased cardiac output 16. 4) Congestive heart failure: Is a condition which occurs due to dysfunctional systoly, diastoly and myocardial contractility resulting in an inability to maintain cardiac output 17 and 5) vascular toxicity: Is a condition which results from structural and functional alterations of vascular endothelial cells induced by oxidative stress or accumulation of toxins in these cells 18. Other notable factors that lead to compromise in function of cardiomyocytes include lipotoxicity, oxidative stress, mitochondrial dysfunction and ischemic reperfusion etc. 19.

    The FDA Adverse Event Reporting System (FAERS) has been an invaluable resource in identifying occurrence and providing details related to drug-induced adverse cardiotoxic events thus offering potential insights to the possible mechanisms of toxicity 20. The following link (https://www.fda.gov/Drugs/DrugSafety/ucm504617.htm) is an example of a safety announcement by the FDA based on adverse events reporting of the cardiac adverse events to loperimide (Imodium®), a drug indicated for control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. Several prominent drugs, for non-life-threatening diseases, such as Terfenadine, Viioxx, and Avandia were withdrawn from the market due to drug-induced cardiotoxicity. Well-documented classes of drugs that exhibit cardiotoxicity include anti-cancer drugs particularly anthracyclines, antipsychotics, antidepressants, some antibiotics, anti-inflammatory agents, antiarrhythmics, anesthetics, and beta-blockers among others. 21.

    Cardiovascular Risk Factors, Obesity and Diabetes, can Increase the Potential for Drug-induced Cardiotoxicity

    Disease states such as obesity and diabetes confer increased susceptibility to cardiovascular diseases 22. The insulin resistant state which arises as a consequence to obesity, as well as diabetes are notable predictors of cardiovascular morbidity and mortality and are also independent risk factors for death in patients with heart failure 23, 24, 25. The insulin resistant state alters insulin signaling in the heart, which compromises the contribution from glucose oxidation and consequently increases fatty acid oxidation, in order to maintain a constant energy supply to the heart 23. Obesity is also associated with other risk factors for developing cardiac failure, such as hypertension, hyperlipidemia 26 and inflammation 24. The presence of excess circulating free fatty acids (FFAs) in obesity can increase the delivery of FFAs to the heart resulting in cadiomyocyte lipotoxicity, augment reactive oxygen species (ROS) production and increase oxidative stress. 27. Studies have shown that the accumulation of ROS in the myocardium consequent to hyperglycemia in the diabetic state can trigger myocardial apoptosis leading to diabetic cardiomyopathy 28. Excess circulating FFAs in obesity activate toll receptors stimulating the downstream activation of the NFκB pathway resulting in augmented production of pro-inflammatory cytokines including TNFα and IL-6 29. TNFα can further increase the production of IL-6 and macrophage chemoattractant protein, (MCP-1), which plays a role in macrophage recruitment 24, 30. These pro-inflammatory cytokines are prominent in stimulating the formation of atherosclerotic plaques 31. The consequent state of chronic low-grade inflammation in obesity further plays a key role in the development of insulin resistance 24, 32 . Obesity and inflammation are associated with the development of endothelial dysfunction 33. Diabetes is strongly associated with cardiovascular diseases and symptoms including atrial fibrillation, atrial flutter, coronary artery disease and left ventricular hypertrophy 34 and can contribute to the development of diabetic cardiomyopathy. 35 Thus, the pathophysiological changes accompanying obesity and diabetes exert their effects both at the cellular and systemic levels resulting in cardiac dysfunction 23, 36, which over time can alter myocardial structure and function causing heart failure 22. Hence pre-existence of these cardiovascular risk factors in patients can augment drug-induced cardiotoxicity.

    Current Preclinical Testing Strategies and Model Systems used in in vitro Drug Testing

    The model systems frequently used in investigating cardiotoxicities, in particular, proarrhythmic risk are transgenic in vitro systems such as Human Embryonic Kidney (HEK) cells and Chinese Hamster Ovary (CHO) cells expressing heterologous ion channel systems 37 with a focus on identifying mainly the arrhythmogenic effects of drugs. Although these systems to a large extent have contributed to understanding ion channel defects and arrhythmogenic mechanisms, they have limitations in accurately predicting toxicities in humans, due to the inability of these cell systems to accurately reproduce the human cardiac physiology and the clinical manifestations of cardiac toxicities. The rodent cell line H9C2 from rat heart 38 is another model that has been used to examine drug-induced toxicities by chemotherapeutic agents 39, 40. It is noted that the H9C2 cells exhibit features that are morphologically distinct from human cardiomyocytes and are also less mature than the human adult cardiomyocytes 37. Primary adult human ventricular cardiomyocytes are appropriate model systems for toxicity testing to recapitulate human physiologically functional cardiomyocytes of the human heart 41. However, these cells are difficult to obtain and cannot be maintained and propagated long term in culture 42. Alternatively, human pluripotent stem cells, such as embryonic stem (ES) cells, which are obtained from the blastocyst embryonic stage 43 as well as the iPSCs, which are derived from reprograming somatic cells 44 can be induced to differentiate into any somatic cell type including cardiomyocytes 45. The particular advantage of the iPSCs over the ES cells is twofold i) they overcome the ethical concerns associated with ES cells ii) while both ES and iPSCs can serve as an infinite source of cells, iPSCs can also be generated from somatic cells from individuals with disease enabling the modeling of the disease phenotype in a dish 46. In vivo model systems including rodent and more recently Zebrafish 37, 47 have also been used as models to test for cardiotoxicity. However, given the varied structure and morphology of the cardiomyocytes and the electrophysiological characteristics and profiles of the various repolarizing and depolarizing currents channels in these non-human model systems, they may not effectively predict cardiotoxicity in humans.

    To enable safety pharmacology efforts, several guidelines for preclinical safety using in vitro and in vivo approaches have been put forth by the US Food and Drug Administration and International Coalition for Harmonization (ICH) including i) ICH S7(A) Safety Pharmacology Studies for Human Pharmaceuticals ii) ICH S7(B) Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals, iii) ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals, in order to minimize the risks that may be associated with cardiovascular toxicity during drug development. These guidelines mainly place emphasis on assessing proarrhythmic risk, which is the most common risk associated with drug-induced cardiotoxicity. The approaches currently used for cardiotoxicity determination are i) an in vitro assay for the Ether-a-go-go-Related gene (hERG), which examines the blockage of the repolarizing potassium channel current (hERG/Ikr) by the drug, and ii) non-clinical in vivo assessment of QT prolongation. However, blockage of hERG constitutes only one out of several cardiac current channels which result in proarrhythmia, when blocked. Hence, the strategy of only examining the blockage of a single ion channel is increasingly being recognized as an imperfect measure ventricular repolarization 48, 49. Also, this much relied on in vitro assay for hERG, although highly sensitive, has only low specificity 49. Furthermore, nonclinical QT prolongation assays are not fully predictive of the QT prolongation in humans 48. Hence, although these guidelines have proven useful in decreasing drug-induced cardiotoxicity by enabling the early detection of potentially torsadogenic drugs, incidences of false positive results have led to the incorrect/inappropriate assignment of some drugs as torsadogenic 48. In the case of some drugs, these approaches have also resulted in false negative results, leading to drug attrition 50, 51, 52. In order to address these issue, partnered efforts by multidisciplinary scientists, representing international regulatory groups, industry and academia are underway for the development of more newer approaches to assess proarrhythmic risk under the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiatives 49, 53.

    Limitations of Current Models and Strategies

    The move from animal and non-cardiac human cell lines to human human iPSC-derived cardiomyocytes are enabling the assessment of cardiotoxicity due to proarrhythmic cardiotoxic risk in more relevant human models. A significant limitation to the use of IPSC-derived cardiomyocytes is that they are recognized to exhibit a more neonatal phenotype as opposed to the preferred adult-like phenotype 54. Many studies are addressing this issue to obtain a more adult-like phenotype in the IPSC-derived cardiomyocytes 54. However, a caveat in the use of in vitro iPSC-derived cardiomyocytes used in safety pharmacology studies and early drug development is that these iPSC-derived cardiomyocytes are derived from healthy individuals and are less representative of the pathophysiological state seen in patients to whom drugs are prescribed. Individuals with cardiovascular risk factors who are vulnerable to heart diseases demonstrate pathophysiological modifications in the hearts due to either i) genetic causes, for example, SNPs in specific heart channels causing channelopathies and resulting in cardiac dysfunction or ii) presence of obesity and diabetes, which are prominent risk factors of heart disease, making these individuals more susceptible to cardiotoxicity. Hence, the use of appropriate disease models that can model cardiovascular disease states will vastly improve the safety/toxicity assessments of drugs and may further decrease drug attrition resulting from disparities in susceptibility to cardiotoxicity in cardiovascular disease states compared to healthy individuals from whom in vitro models are currently being derived.

    Cardiovascular Disease Models and its Applications

    Many recent studies have successfully demonstrated the development of in vitro disease models of cardiovascular diseases that can be used in cardiac safety/toxicity testing to more accurately predict drug-induced clinical cardiotoxicity such as, congenital monogenic cardiac arrhythmic syndromes also known as cardiac channelopathies 55, 56 due to mutations in specific cardiac ion channels. Examples include mitations in KCNQ1, KCNH2, causing Long QT syndrome; mutations in Ryanodine receptor (RyR) leading to Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) as well as other conditions such as Brugada Syndrome 55, 56, 57.

    Other types of hereditary cardiovascular disease conditions that have been modeled using iPSC-derived cardiomyocytes include dilated cardiomyopathy derived from a patient carrying a point mutation in the gene TNNT2, which encodes the sarcomeric protein troponin T 58. These patient-specific IPSC-derived cardiomyocytes from patients with this condition demonstrated altered Ca2+ currents, abnormal contractility and abnormal sarcomeric organization compared to iPSC-derived cardiomyocytes from healthy individuals. The phenotype observed was corrected by treatment with the β blocker, metoprolol demonstrating the precise capture of the phenotype in this model. Similarly, Lan et al. 59 modeled hypertrophic cardiomyopathy, which is a common form of congenital cardiac dysfunction resulting from the missense mutation of the MYH7 gene. These iPSC-derived cardiomyocytes demonstrated hypertrophic cardiomyocytes with abnormal calcium handling and electrophysiological function. Wang et al 60 have successfully modeled Barth syndrome which is a form of mitochondrial myopathy that can cause cardiac dysfunction.

    While monogenic cardiac disorders are prevalent, the more common cause of cardiovascular disorders is of the polygenic form, which arises from a number of complex conditions such as dysfunctional metabolic disorders including diabetes and obesity. Drawnel et al. 58 were able to successfully induce and model the phenotypic state of diabetic cardiomyopathy by exposure of human iPSCs from normal healthy individuals exposed to a diabetic-milieu in culture, which demonstrated characteristic disease features including cellular hypertrophy, disorganized sarcomeres, altered calcium transients, intracellular lipid accumulation and oxidative stress. In another study. Burridge et al. 61 modeled the phenotypic characteristics of doxorubicin-induced cardiotoxicity in iPSC-derived cardiomyocytes from patients who experienced increased doxorubicin-induced cardiotoxicity compared to iPSC-derived cardiomyocytes from those who did not experience doxorubicin-induced cardiotoxicity. The iPSC-derived cardiomyocytes from the doxorubicin-sensitive patients consistently demonstrated increased sensitivity in culture, similar to the patients from whom the iPSCs were derived, and was accompanied by decreased cell viability, impaired mitochondrial and metabolic function, impaired calcium handling, decreased antioxidant pathway activity, and increased ROS production 61. These studies clearly demonstrate the possibilities of effectively capturing and modeling the defective phenotype in a dish, which can be used for drug safety/toxicity testing. The use of in vitro iPSC-derived cardiac disease models from subjects with genetic and/or environmental causes of metabolic and cardiovascular diseases resulting in increased cardiovascular risk, can improve the identification of toxicity early in preclinical studies. Ultimately, clinical trials can be made safer by identifying risks in phenotypically-relevant iPSC models in nonclinical assessments.

    Conclusions

    Drug-induced cardiovascular toxicity has been documented with several classes of therapeutic drugs necessitating focus on cardiac safety studies early in drug development. While the field has come a long way in the detection and identification of drug-induced cardiotoxicity particularly arrhythmia using various in vitro model systems, including animal, non-cardiac human cell lines, primary human ventricular cardiomyocytes and more recently human iPSC-derived cadiomyocyte models, drug attrition, withdrawals and non-approvals due to cardiac side effects in patients continue to be of concern. While the development of newer tests and methodologies as part of the CiPA initiative will continue to improve safety pharmacology testing, the use of in vitro human iPSC-derived cells that model cardiovascular disease due to both genetic and non-genetic causes can be beneficial in detecting safety and/or increased susceptibility to toxicity. Human in vitro disease models employed early in preclinical stages will, therefore, be a valuable addition in making the clinical trials safer for patients, enhancing safety testing approaches and in further reducing and preventing late stage drug attrition and post market withdrawals.

    Disclaimer:

    This document has been reviewed in accordance with the United States Food and Drug Administration (FDA) policy and approved for publication. The views presented in this article do not necessarily represent the views of the Food and Drug Administration

    References

    1.Khanna I. (2012) Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today,7(19-20):. 1088-102.
    2.Turner R A H a J R. (2011) The Current Regulatory Landscape for Cardiac and Cardiovascular Safety Assessments: Part I. , RAPS Regulatory Focus,(January2011) 16(1), 43-48.
    3.Turner R A H a J R. (2011) The Current Regulatory Landscape for Cardiac and Cardiovascular safety Assesments-Part II RAPS Regulatory Focus,(February2011)16(1):. 38, 41-42.
    4.Kola I, Landis J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 3(8), 711-5.
    5.Cook D. (2014) Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 13(6), 419-31.
    6.Ferri N. (2013) Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther. 138(3), 470-84.
    7.J A Dykens, L D Marroquin, Will Y. (2007) Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev Mol Diagn. 7(2), 161-75.
    8.Fung M. (2001) Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Information Journal. 35(1), 293-317.
    9.htm https www cdc govnchsfastatsobesity-overweight, ObesityandOverweight..
    10.. https://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html,2014National Diabetes Statistics Report
    11.J X Moore, Chaudhary N, Akinyemiju T. (2017) Metabolic Syndrome Prevalence by Race/Ethnicity and Sex. in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis 14, 24.
    12.D A Pijnappels, Gregoire S, S M Wu. (2010) The integrative aspects of cardiac physiology and their implications for cell-based therapy. , Ann N Y Acad Sci 1188, 7-14.
    13.B P Delisle. (2004) Biology of cardiac arrhythmias: ion channel protein trafficking. Circ Res. 94(11), 1418-28.
    14.J E Tisdale. (2016) Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can PharmJ(Ott). 149(3), 139-52.
    15.Shimizu I, Minamino T. (2016) Physiological and pathological cardiac hypertrophy. , J Mol Cell Cardiol 97, 245-62.
    16.Harvey P A, Leinwand L A. (2011) The cell biology of disease: cellular mechanisms of cardiomyopathy. , J Cell Biol 355-65.
    17.Braunwald E. (2013) Heart failure. , JACC Heart Fail 1(1), 1-20.
    18.Taimeh Z. (2013) Vascular endothelial growth factor in heart failure. Nat Rev Cardiol. 10(9), 519-30.
    19.Kalogeris T. (2012) Cell biology of ischemia/reperfusion injury. , Int Rev Cell Mol Biol 298, 229-317.
    20.Mizutani S. (2014) Pharmacoepidemiological characterization of drug-induced adverse reaction clusters towards understanding of their mechanisms. Comput Biol Chem. 50, 50-9.
    21.R L Page, 2nd. (2016) Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 134(6), 32-69.
    22.P E Scherer, J A Hill. (2016) Obesity, Diabetes, and Cardiovascular Diseases: A Compendium. Circ Res. 118(11), 1703-5.
    23.E D Abel, S E Litwin, Sweeney G. (2008) Cardiac remodeling in obesity. Physiol Rev. 88(2), 389-419.
    24.Mathieu P, Lemieux I, J P Despres. (2010) Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther. 87(4), 407-16.
    25.J A Beckman, M A Creager. (2016) Vascular Complications of Diabetes. Circ Res. 118(11), 1771-85.
    26.C J Lavie, R V Milani, H O Ventura. (2009) Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. , J Am Coll Cardiol 53(21), 1925-32.
    27.E D Abel, K M O'Shea, Ramasamy R. (2012) Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol. 32(9), 2068-76.
    28.Cai L. (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 51(6), 1938-48.
    29.Avlas O. (2011) Toll-like receptor 4 stimulation initiates an inflammatory response that decreases cardiomyocyte contractility. Antioxid Redox Signal. 15(7), 1895-909.
    30.Lyngso D, Simonsen L, Bulow J. (2002) Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. , J Physiol 543, 379-86.
    31.D P Ramji, T S Davies. (2015) Cytokines inatherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 26(6), 673-85.
    32.Varma V. (2009) Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. , Am J Physiol Endocrinol Metab 296(6), 1300-10.
    33.Meyers M R, Gokce N. (2007) Endothelial dysfunction in obesity: etiological role in atherosclerosis. , Curr Opin Endocrinol Diabetes Obes 14(5), 365-9.
    34.Movahed M R, Hashemzadeh M, Jamal M M. (2005) Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. , Int J Cardiol 105(3), 315-8.
    35.R F Mapanga, M F Essop. (2016) Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways. Am J Physiol Heart Circ Physiol. 310(2), 153-73.
    36.M S Shah, Brownlee M. (2016) Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes. Circ Res. 118(11), 1808-29.
    37.Sheng C C. (2016) 21st Century Cardio-Oncology. JACC: Basic to Translational Science. 1(5), 386-398.
    38.Hescheler J. (1991) Morphological, Biochemical and Electrophysiological Characterization of a Clonal Cell (H9c2) Line from Rat-Heart. , Circulation Research 69(6), 1476-1486.
    39.V A Sardao. (2009) Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biology and Toxicology. 25(3), 227-243.
    40.Will Y. (2008) Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 106(1), 153-61.
    41.S D Bird. (2003) The human adult cardiomyocyte phenotype. Cardiovasc Res. 58(2), 423-34.
    42.Bistola V. (2008) Long-term primary cultures of human adult atrial cardiac myocytes: cell viability, structural properties and BNP secretion in vitro. , Int J Cardiol 131(1), 113-22.
    43.Y J Lou, X G Liang. (2011) Embryonic stem cell application in drug discovery. Acta Pharmacol Sin. 32(2), 152-9.
    44.V K Singh. (2015) Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol. 3, 2.
    45.C L Mummery. (2012) Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res. 111(3), 344-58.
    46.Laustriat D, Gide J, Peschanski M. (2010) Human pluripotent stem cells in drug discovery and predictive toxicology. Biochem Soc Trans. 38(4), 1051-7.
    47.M B Thomsen. (2006) Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther. 112(1), 150-70.
    48.Polak S. (2015) Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates. , AAPS J 17(4), 1025-32.
    49.Colatsky T. (2016) The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress. , J Pharmacol Toxicol Methods 81, 15-20.
    50.Liang P. (2013) Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 127(16), 1677-91.
    51.A E Lacerda. (2008) Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther. 324(2), 427-33.
    52.Rodriguez-Menchaca A A. (2008) The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. , Proc Natl Acad Sci U S A 105(4), 1364-8.
    53.P T Sager. (2014) Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 167(3), 292-300.
    54.F M Drawnel. (2014) Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 9(3), 810-21.
    55.Tang S. (2016) Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery. J Med Chem. 59(1), 2-15.
    56.Rajamohan D. (2013) Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays. 35(3), 281-98.
    57.Saric T. (2014) Induced pluripotent stem cells as cardiac arrhythmic in vitro models and the impact for drug discovery. Expert Opin Drug Discov. 9(1), 55-76.
    58.Sun N. (2012) Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 4(130), 130-47.
    59.Lan F. (2013) Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 12(1), 101-13.
    60.Wang G. (2014) Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 20(6), 616-23.
    61.P W Burridge. (2016) Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 22(5), 547-56.